In HCC, studies have shown that miR-101 inhibits tumorigenicity and participates in cellular life activities by targeting genes such as Mcl-1, EED, EZH2, and VEGF [18–22]. The gene discussed is EZH2; the disease is hepatocellular carcinoma.